Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Recruiting

Phase 3

Zeleciment BasivarsenEfficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1

Sponsor:

Dyne Therapeutics

Code:

NCT07486934

Conditions

Myotonic Dystrophy Type 1 (DM1)

DM1

Myotonic Dystrophy

Steinert Disease

Steinert

Eligibility Criteria

Sex: All

Age: 16+

Healthy Volunteers: Not accepted

Interventions

zeleciment basivarsen (DYNE-101)

Placebo

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-04-24. This information was provided to ClinicalTrials.gov by Dyne Therapeutics on 2026-04-21.